Effect of plasminogen activator inhibitor-1 on adipogenesis in vivo

 

 Buy Article Permissions and Reprints

Summary

To study the functional role of plasminogen activator inhibitor-1 (PAI-1) in obesity, the effect of its overexpression on de novo adipogenesis was evaluated in murine models in vivo. Therefore, 3T3-F442A preadipocytes expressing murine PAI-1 (mPAI-1) or control cells were injected in the back of male NUDE mice, which were fed a high-fat diet (HFD) for four weeks. De novo fat pads that formed from the PAI-1 expressing cells were larger (21 ± 2.4 mg vs. 14 ± 1.4 mg; p = 0.017) and showed a higher adipocyte density (373 ± 28 mm^-2 vs. 301 ± 12 mm^-2; p = 0.03) as compared to those formed from control cells. In a second model, male NUDE mice were injected in the tail vein with an adenoviral construct expressing mPAI-1 or with the empty vector, and three days later with 3T3-F442A cells. After four weeks of HFD, total body weight and de novo fat pad weight were comparable for both groups. Mild adipocyte hypotrophy was observed in the de novo fat pads of the PAI-1 overexpressing mice (1180 ± 33 µm² vs. 1285 ± 32 µm²; p= 0.024), whereas the blood vessel size was significantly smaller than in controls (30 ± 1.8 µm² vs. 63 ± 3.6 µm²; p < 0.0001). Thus, the effect of local or systemic PAI-1 (over)expression on adipocyte or blood vessel size and density of de novo formed fat pads appears to be different, and concentration-dependent. Whereas local expression resulted in larger fat pads, systemic overexpression had no effect on de novo adipogenesis, although angiogenesis appeared to be impaired.

• References

• 1 Crandall DL, Hausman GJ, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 1997; 4: 211-232.
  CrossrefPubMedGoogle Scholar
• 2 Christiaens V, Scroyen I, Lijnen HR. Role of proteolysis in development of murine adipose tissue. Thromb Haemostasis 2008; 99: 290-294.
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Alessi MC, Peiretti F, Morange P. et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867.
  CrossrefPubMedGoogle Scholar
• 4 Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2: 568-582.
  PubMedGoogle Scholar
• 5 Alessi MC, Bastelica D, Morange P. et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374-1380.
  CrossrefPubMedGoogle Scholar
• 6 Mavri A, Stegnar M, Krebs M. et al. Impact of adi-pose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arteriosclerosis Thromb Vasc Biol 1999; 19: 1582-1587.
  CrossrefPubMedGoogle Scholar
• 7 Morange PE, Lijnen HR, Alessi MC. et al. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arteriosclerosis Thromb Vasc Biol 2000; 20: 1150-1154.
  CrossrefPubMedGoogle Scholar
• 8 Lijnen HR. Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice. Thrombosis Haemost 2005; 93: 816-819.
  PubMedGoogle Scholar
• 9 Ma LJ, Mao SL, Taylor KL. et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 5: 336-346.
  PubMedGoogle Scholar
• 10 Schafer K, Fujisawa K, Konstantinides S. et al. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15: 1840-1842.
  CrossrefPubMedGoogle Scholar
• 11 Liang X, Kanjanabuch T, Mao SL. et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol 2006; 290: E103-E113.
  PubMedGoogle Scholar
• 12 Scroyen I, Christiaens V, Lijnen HR. No functional role of plasminogen activator inhibitor-1 in murine adipogenesis or adipocyte differentiation. J Thromb Haemost 2007; 5: 139-145.
  CrossrefPubMedGoogle Scholar
• 13 Lijnen HR, Maquoi E, Morange P. et al. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23: 78-84.
  CrossrefPubMedGoogle Scholar
• 14 Green H, Kehinde O. Spontaneous heritable changes leading to increased adipose conversion in 3T3 cells. Cell 1976; 7: 105-113.
  CrossrefPubMedGoogle Scholar
• 15 Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995; 74: 1305-1309.
  Article in Thieme ConnectPubMedGoogle Scholar
• 16 Mandrup S, Loftus TM, MacDougald OA. et al. Obese gene expression at in vivo levels by fat pads derived from s.c. implanted 3T3-F442A preadipocytes. Proc Natl Acad Sci USA 1997; 94: 4300-4305.
  CrossrefPubMedGoogle Scholar
• 17 Neels JG, Thinnes T, Loskutoff DJ. Angiogenesis in an in vivo model of adipose tissue development. FASEB J 2004; 18: 983-985.
  CrossrefPubMedGoogle Scholar
• 18 Van Linthout S, Lusky M, Collen D. et al. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector. Gene Ther 2002; 9: 1520-1528.
  CrossrefPubMedGoogle Scholar
• 19 Lijnen HR, Maquoi E, Demeulemeester D. et al. Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Thromb Haemost 2002; 88: 345-353.
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Bijnens AP, Gils A, Knockaert I. et al. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J Biol Chem 2000; 275: 6375-6380.
  CrossrefPubMedGoogle Scholar
• 21 Demeulemeester D, Collen D, Lijnen HR. Effect of matrix metalloproteinase inhibition on adipose tissue development. Biochem Biophys Res Comm 2005; 329: 105-110.
  CrossrefPubMedGoogle Scholar
• 22 Laitinen L. Griffonia simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem J 1987; 19: 225-234.
  CrossrefPubMedGoogle Scholar
• 23 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-1084.
  Article in Thieme ConnectPubMedGoogle Scholar
• 24 De Taeye BM, Novitskaya T, Gleaves L. et al. Bone marrow plasminogen activator inhibitor-1 influences the development of obesity. J Biol Chem 2006; 281: 32796-32805.
  CrossrefPubMedGoogle Scholar
• 25 Fay WP, Parker AC, Condrey LR. et al. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90: 204-208.
  PubMedGoogle Scholar
• 26 Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3: 85-101.
  CrossrefPubMedGoogle Scholar
• 27 Bajou K, Masson V, Gerard RD. et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001; 152: 777-784.
  CrossrefPubMedGoogle Scholar
• 28 Bajou K, Noel A, Gerard RD. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-928.
  CrossrefPubMedGoogle Scholar
• 29 Gutierrez LS, Schulman A, Brito-Robinson T. et al. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60: 5839-5847.
  PubMedGoogle Scholar
• 30 Soff GA, Sanderowitz J, Gately S. et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995; 96: 2593-2600.
  CrossrefPubMedGoogle Scholar
• 31 Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angio-genesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-1117.
  CrossrefPubMedGoogle Scholar
• 32 Lambert V, Munaut C, Carmeliet P. et al. Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. Invest Ophtalmol Vis Sci 2003; 44: 2791-2797.
  CrossrefPubMedGoogle Scholar
• 33 Devy L, Blacher S, Grignet-Debrus C. et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002; 16: 147-154.
  CrossrefPubMedGoogle Scholar
• 34 Lijnen HR, Alessi MC, Frederix L. et al. Tiplaxtinin impairs nutritionally induced obesity in mice. Thromb Haemost 2006; 96: 731-737.
  Article in Thieme ConnectPubMedGoogle Scholar
• 35 Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell Differ Dev 1990; 32: 319-327.
  CrossrefPubMedGoogle Scholar
• 36 Kjoller L, Kanse SM, Kirkegaard T. et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420-429.
  CrossrefPubMedGoogle Scholar
• 37 Stefansson S, Lawrence DA, Argraves WS. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipo-protein receptor-related proteins 1 and 2. J Biol Chem 1996; 271: 8215-8220.
  CrossrefPubMedGoogle Scholar
• 38 Chazaud B, Ricoux R, Christov C. et al. Promigra-tory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 2002; 160: 237-246.
  CrossrefPubMedGoogle Scholar
• 39 Lambert V, Munaut C, Noel A. et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 2001; 15: 1021-1027.
  CrossrefPubMedGoogle Scholar
• 40 Morange PE, Bastelica D, Bonzi MF. et al. Influence of t-PA and u-PA on adipose tissue development in a murine model of diet-induced obesity. Thromb Haemost 2002; 87: 306-310.
  Article in Thieme ConnectPubMedGoogle Scholar
• 41 Hoover-Plow J, Ellis J, Yuen L. In vivo plasminogen deficiency reduces fat accumulation. Thromb Haemost 2002; 87: 1011-1019.
  Article in Thieme ConnectPubMedGoogle Scholar
• 42 Lijnen HR. Deficiency of alpha2-antiplasmin does not affect murine adipose tissue development. J Thromb Haemost 2007; 5: 420-421.
  CrossrefPubMedGoogle Scholar
• 43 Lijnen HR, Frederix L, Scroyen I. Deficiency of plasminogen activator inhibitor-2 impairs nutritionally induced murine adipose tissue development. J Thromb Haemost 2007; 5: 2259-2265.
  CrossrefPubMedGoogle Scholar